ADAP News and Press, Adaptimmune Therapeutics plc From 09/11/23

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - September 11, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, today announces that Karen Chagin, MD has joined the Company as its Senior Vice President of Early-Stage Devel...

2023-08-09 10:18:02 ET Adaptimmune Therapeutics plc (ADAP) Q2 2023 Results Conference Call August 09, 2023 08:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, Late S...

2023-08-09 07:56:21 ET Adaptimmune press release ( NASDAQ: ADAP ): Q2 GAAP EPS of -$0.02 beats by $0.19 . Revenue of $5.13M (-7.4% Y/Y) misses by $1.54M . The Company believes that its existing cash, cash equivalents and marketable securities, together with the...

2023-08-08 14:26:41 ET Adaptimmune ( NASDAQ: ADAP ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.18 and the consensus Revenue Estimate is $6.67M. Over the last 1 year, ADAP has beaten EPS...

2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 3, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US ma...

2023-06-01 17:02:47 ET Adaptimmune ( NASDAQ: ADAP ) said that it has completed its planned merger with fellow T-cell therapy developer TCR2 ( TCRR ). The immunology companies announced the merger in March. After the closing Adaptimmune shareholders own around 75% of the comb...

First marketed engineered T-cell therapy for a solid tumor; BLA for afami-cel on track to complete submission in mid-2023 Compelling clinical data with late-stage programs targeting MAGE-A4 and mesothelin Preclinical programs targeting PRAME and CD70 in IND-enabling studies Adaptimmune funded ...

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022) Median overall survival (mOS) was ~17 months Patients with a RECIST response have a 12-month OS prob...

2023-05-12 13:09:08 ET Adaptimmune Therapeutics plc (ADAP) Q1 2023 Earnings Conference Call May 12, 2023, 08:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Officer Dennis Williams - Senior Vice President, La...